Effects of Salmeterol on Autonomic Nervous System

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Salmeterol

At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.

Trial Locations (1)

37075

GSK Investigational Site, Göttingen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01536587 - Effects of Salmeterol on Autonomic Nervous System | Biotech Hunter | Biotech Hunter